drugset / Trial / NCT06911502
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Timeline
- Start
- 2025-07-28
- Primary completion
- 2028-04-24
- Completion
- 2030-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bendamustine | Small molecule | — | — |
| Comparator | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Subject | Golcadomide | Other / unclassified | — | — |
| Comparator | Lenalidomide | Other / unclassified | — | — |
| Comparator | Prednisolone | Other / unclassified | — | — |
| Comparator | Prednisone | Other / unclassified | — | — |
| Comparator | Vincristine | Small molecule | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |